1 receptor agonists may reduce obesity related cancer risk through metabolic and direct cellular mechanisms, according to new evidence
GLP-1 Receptor Agonists Show Potential in Obesity Related Cancer
GLP-1 receptor agonists may offer benefits beyond diabetes and obesity management by reducing the risk of several obesity related cancers, according to a comprehensive review of current evidence. Researchers report that these medications influence multiple biological pathways involved in tumor development while emphasizing that dedicated cancer focused randomized clinical trials remain essential before their use can be recommended in oncology
Originally developed to improve glycemic control and promote weight loss, GLP-1 receptor agonists have increasingly attracted attention for their possible role in cancer prevention. The review highlights evidence suggesting that improvements in insulin sensitivity, reductions in chronic inflammation, and sustained weight loss may all contribute to lowering cancer risk. In addition, laboratory studies indicate these therapies may directly suppress cancer cell proliferation, promote apoptosis, regulate immune surveillance, and inhibit several oncogenic signaling pathways.
GLP-1 Receptor Agonists and Clinical Evidence
Observational studies involving large patient populations have reported associations between GLP-1 receptor agonist use and lower rates of several obesity related cancers, including endometrial, ovarian, liver, colorectal, pancreatic, prostate, and certain gynecologic malignancies. Meta analyses and real world studies have also suggested favorable trends without demonstrating an increased overall cancer risk compared with other diabetes therapies
Despite these encouraging findings, the authors caution that nearly all available clinical evidence comes from observational research or secondary analyses of cardiovascular and metabolic trials that were not designed to assess cancer outcomes. As a result, important questions about causality remain unanswered
Safety Remains an Important Consideration
The review also addresses longstanding concerns regarding thyroid cancer and pancreatitis. Although rodent studies initially raised concerns about medullary thyroid carcinoma, large human clinical trials and subsequent analyses have not demonstrated a significant increase in thyroid cancer risk. Similarly, early concerns surrounding pancreatitis and pancreatic cancer have largely been alleviated by more robust evidence. Gastrointestinal adverse effects remain the most common side effects and are generally transient and manageable.
The authors conclude that GLP-1 receptor agonists represent an intriguing area of investigation in cancer prevention and adjunctive cancer therapy. However, they stress that well designed randomized clinical trials with cancer specific endpoints and extended follow up are needed before these agents can be routinely incorporated into oncology practice
Muscogiuri G et al. Role of GLP-1 receptor agonists in the prevention and treatment of obesity related cancer. Internal and Emergency Medicine. 2026. https://doi.org/10.1007/s11739-026-04458-z
Featured Image: AntonioDiaz on Adobe Stock
Author:
Rana Zarour
